Skip to content

Study · Observational study · 2025

1 result

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion.

Khalid SI, Wang R, Abou-Mrad T, Massaad E, Arena JD, Ghenbot Y, Golubovsky JL, Ozturk AK, Shin JH

World neurosurgery8 Oct 2025

PMID41072911 (opens in a new tab)DOI10.1016/j.wneu.2025.124553 (opens in a new tab)PepBankPUB-41072911
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

BackgroundOsteoporosis increases the risk of postoperative complications and reoperation following spinal fusion due to reduced bone quality. Bone-strengthening medications are frequently employed to mitigate these risks. This study evaluates the impact of osteoporosis and osteoporosis medications on the incidence of additional spine surgeries and postoperative complications following lumbar fusion.MethodsWe conducted a retrospective cohort study using a national database of patients who underwent transforaminal lumbar interbody fusion between 2010 and April 2023. Patients were exactly matched 1:1 for age, gender, and comorbidities. Osteoporosis medications included bisphosphonates (alendronate, ibandronate, and risedronate), parathyroid hormone analogs (teriparatide and abaloparatide), and monoclonal antibodies (denosumab and romosozumab). Logistic regression and Kaplan-Meier survival compared rates of additional spine surgeries and postoperative complications and assessed the effect of osteoporosis medications.ResultsAfter matching, 24,145 patients with and without osteoporosis were identified. Osteoporosis patients had a higher incidence of all-cause need for additional spine surgery (odds ratio [OR] = 1.40; 95% confidence interval [CI]: 1.28-1.53). Although medication effects did not reach statistical significance, teriparatide (OR = 1.06; 95% CI: 0.41-2.21), abaloparatide (OR = 3.04; 95% CI: 0.71-8.95), and denosumab (OR = 1.35; 95% CI: 0.33-3.70) demonstrated moderate change in risk for reoperation. Osteoporosis patients had higher rates of urinary tract infections (OR = 1.18; 95% CI: 1.08-1.29), pneumonia (OR = 1.25; 95% CI: 1.07-1.45), and deep vein thrombosis (OR = 1.40; 95% CI: 1.16-1.69).ConclusionsOsteoporosis is linked to higher reoperation and medical complications following lumbar fusion. Although osteoporosis medications did not significantly alter reoperation risk, their potential role in perioperative optimization requires further investigation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    After lumbar fusion, abaloparatide use was not significantly associated with reoperation risk.

    In plain wordsAfter lumbar fusion, abaloparatide use was not significantly linked to reoperation risk.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeReoperation risk
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    3.04
    abaloparatide
    95% CI
    0.71 to 8.95
    abaloparatide

    Source sentences

    Summary
    Although medication effects did not reach statistical significance, teriparatide (OR = 1.06; 95% CI: 0.41-2.21), abaloparatide (OR = 3.04; 95% CI: 0.71-8.95), and denosumab (OR = 1.35; 95% CI: 0.33-3.70) demonstrated moderate change in risk for reoperation.
    2 context sentences
    Summary · context
    We conducted a retrospective cohort study using a national database of patients who underwent transforaminal lumbar interbody fusion between 2010 and April 2023.
    Summary · context
    Osteoporosis medications included bisphosphonates (alendronate, ibandronate, and risedronate), parathyroid hormone analogs (teriparatide and abaloparatide), and monoclonal antibodies (denosumab and romosozumab).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.